Protocol for the Examination of Specimens From Patients With Melanoma of the Skin

Protocol applies to melanoma of cutaneous surfaces only.

Based on AJCC/UICC TNM, 7th edition
Protocol web posting date: February 2015

Procedures
• Biopsy
• Excision
• Sentinel node examination
• Regional node examination

Authors
David P. Frishberg, MD, FCAP*
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

Charles Balch, MD
Departments of Surgery, Oncology, and Dermatology, Johns Hopkins University, Baltimore, Maryland

Bonnie L. Balzer, MD, PhD, FCAP
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

A. Neil Crowson, MD, FCAP
Regional Medical Laboratory, Departments of Dermatology, Pathology and Surgery, University of Oklahoma, Tulsa, Oklahoma

Mukund Didolkar, MD, FACS
Division of Surgical Oncology, Sinai Hospital of Baltimore, Department of Surgery, Johns Hopkins University, Baltimore, Maryland

Alexander Lazar, MD, PhD, FCAP
Department of Pathology and Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Jennifer M. McNiff, MD, FASCP
Departments of Dermatology and Pathology, Yale University School of Medicine

Roger R Perry, MD, FACS
Department of Surgery, Eastern Virginia Medical School, Norfolk, Virginia

Victor G. Prieto, MD, PhD, FCAP
Departments of Pathology and Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Priya Rao, MD, FCAP
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

M. Timothy Smith, MD
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina

Bruce Robert Smoller, MD, FCAP
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Mark R. Wick, MD, FCAP
Department of Pathology, University of Virginia Health System, Charlottesville, Virginia

For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author. All other contributing authors are listed alphabetically.

Previous lead contributors: Charles Balch, MD; Raymond Barnhill, MD; Carolyn Compton, MD, PhD; Mark Wick, MD
The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Melanoma Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: Melanoma 3.3.0.1

Summary of Changes
The following changes have been made since the October 2013 release.

Biopsy, Excision, Re-excision

The following note was added:

*Note: For molecular genetic reporting, the CAP Melanoma Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.*
Surgical Pathology Cancer Case Summary

Protocol web posting date: February 2015

MELANOMA OF THE SKIN: Biopsy, Excision, Re-Excision

Select a single response unless otherwise indicated.

Procedure (select all that apply) (Note A)
____ Biopsy, shave
____ Biopsy, punch
____ Biopsy, incisional
____ Excision
____ Re-excision
____ Lymphadenectomy, sentinel node(s)
____ Lymphadenectomy, regional nodes (specify): ____________________________
____ Other (specify): ____________________________
____ Not specified

Specimen Laterality
____ Right
____ Left
____ Midline
____ Not specified

Tumor Site (Note B)
Specify (if known): ____________________________
____ Not specified

Tumor Size (required only if tumor is grossly present)
Greatest dimension: __ cm
+ Additional dimensions: __ x ___ cm
____ Indeterminate (see “Comment”)

Macroscopic Satellite Nodule(s) (required for excision specimens only)
____ Not identified
____ Present
____ Indeterminate

+ Macroscopic Pigmentation
+ ____ Not identified
+ ____ Present, diffuse
+ ____ Present, patchy/focal
+ ____ Indeterminate

Histologic Type (Note C)
Malignant melanoma
____ Melanoma, not otherwise classified
____ Superficial spreading melanoma
____ Nodular melanoma
____ Lentigo maligna melanoma
____ Acral-lentiginous melanoma
____ Desmoplastic and/or desmoplastic neurotropic melanoma
____ Melanoma arising from blue nevus

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
___ Melanoma arising in a giant congenital nevus
___ Melanoma of childhood
___ Nevoid melanoma
___ Persistent melanoma
___ Other (specify): ________________________

**Maximum Tumor Thickness (Note D)**
Specify: ___ mm
At least ___ mm (see “Comment”)
___ Indeterminate (see “Comment”)

**+ Anatomic Level (Note D)**
+ ___ I (Melanoma in situ)
+ ___ II (Melanoma present in but does not fill and expand papillary dermis)
+ ___ III (Melanoma fills and expands papillary dermis)
+ ___ IV (Melanoma invades reticular dermis)
+ ___ V (Melanoma invades subcutis)

**Ulceration (Note E)**
___ Present
___ Not identified
___ Indeterminate

**Margins (select all that apply) (Note F)**

**Peripheral Margins**
___ Cannot be assessed
___ Uninvolved by invasive melanoma
   Distance of invasive melanoma from closest peripheral margin: ___ mm (required for excisions only)
   Specify location(s), if possible: ____________________________
___ Involved by invasive melanoma
   Specify location(s), if possible: ____________________________
___ Uninvolved by melanoma in situ
   Distance of melanoma in situ from closest margin: ___ mm (required for excisions only)
   Specify location(s), if possible: ____________________________
___ Involved by melanoma in situ
   Specify location(s), if possible: ____________________________

**Deep Margin**
___ Cannot be assessed
___ Uninvolved by invasive melanoma
___ Distance of invasive melanoma from margin: ___ mm (required for excisions only)
___ Involved by invasive melanoma

**Mitotic Rate (Note G)**
___ None identified
___ ≥1/mm² (specify number: ______)

**Microsatellitosis (Note H)**
___ Not identified
___ Present
___ Indeterminate
___ Not applicable
Lymph-Vascular Invasion (Note I)
- Not identified
- Present
- Indeterminate

+ Perineural Invasion (Note J)
+ Not identified
+ Present
+ Indeterminate

+ Tumor-Infiltrating Lymphocytes (Note K)
+ Not identified
+ Present, nonbrisk
+ Present, brisk

+ Tumor Regression (Note L)
+ Not identified
+ Present, involving less than 75% of lesion
+ Present, involving 75% or more of lesion
+ Indeterminate

+ Growth Phase (select all that apply) (Note M)
+ Radial
+ Vertical
+ Indeterminate

Lymph Nodes (required only if lymph nodes are present in the specimen) (select all that apply) (Note N)
Number of sentinel nodes examined: ____
Total number of nodes examined (sentinel and nonsentinel): ____
Number of lymph nodes with metastases: ____
+ Extranodal tumor extension:
  + Present
  + Not identified
  + Indeterminate
+ Size of largest metastatic focus: ___ (mm) (for sentinel node)
+ Location of metastatic tumor (for sentinel node)
  + Subcapsular
  + Intramedullary
  + Subcapsular and intramedullary

Pathologic Staging (pTNM) (Note O and Note P)

TNM Descriptors (required only if applicable) (select all that apply)
- m (multiple)
- r (recurrent)
- y (posttreatment)

Primary Tumor (pT)
- pTX: Primary tumor cannot be assessed (eg, shave biopsy or regressed melanoma) (see "Comment")
- pT0: No evidence of primary tumor
- pTis: Melanoma in situ (ie, not an invasive tumor: anatomic level I)

pT1: Melanoma 1.0 mm or less in thickness, with or without ulceration (see Note D)
  - pT1a: Melanoma 1.0 mm or less in thickness, no ulceration, <1 mitoses/mm²
  - pT1b: Melanoma 1.0 mm or less in thickness with ulceration and/or 1 or more mitoses/mm²
pT2: Melanoma 1.01 to 2 mm in thickness, with or without ulceration
  ___ pT2a: Melanoma 1.01 to 2.0 mm in thickness, no ulceration
  ___ pT2b: Melanoma 1.01 to 2.0 mm in thickness, with ulceration
pT3: Melanoma 2.01 to 4.0 mm in thickness, with or without ulceration
  ___ pT3a: Melanoma 2.01 to 4.0 mm in thickness, no ulceration
  ___ pT3b: Melanoma 2.01 to 4.0 mm in thickness, with ulceration
pT4: Melanoma greater than 4.0 mm in thickness, with or without ulceration
  ___ pT4a: Melanoma greater than 4.0 mm in thickness, no ulceration
  ___ pT4b: Melanoma greater than 4.0 mm in thickness, with ulceration

Regional Lymph Nodes (pN)
  ___ pNX: Regional lymph nodes cannot be assessed
  ___ pN0: No regional lymph node metastasis
  pN1: Metastasis in 1 regional lymph node
    ___ pN1a: Clinically occult metastasis (micrometastasis)
    ___ pN1b: Clinically apparent metastasis (macrometastasis)
  pN2: Metastasis in 2 to 3 regional nodes or intralymphatic regional metastasis without nodal metastasis
    ___ pN2a: Clinically occult metastasis (micrometastasis)
    ___ pN2b: Clinically apparent metastasis (macrometastasis)
    ___ pN2c: Satellite or in-transit metastasis without nodal metastasis
  pN3: Metastasis in 4 or more regional lymph nodes, or matted metastatic nodes, or in-transit metastasis or satellites(s) with metastasis in regional node(s)
    ___ No nodes submitted or found

Number of lymph nodes identified: _____
Number containing metastases: _____
Matted nodes:
  ___ Present
  ___ Not identified

Distant Metastasis (pM)
  ___ Not applicable
  + pM1: Distant metastasis (documented in this specimen)
    + pM1a: Metastasis in skin, subcutaneous tissues, or distant lymph nodes
    + pM1b: Metastasis to lung
    + pM1c: Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase (LDH)
      + Specify site, if known: __________________________

  + Additional Pathologic Findings (select all that apply)
    + ___ Nevus remnant
    + ___ Other (specify): ____________________________

  + Comment(s)

Note: For molecular genetic reporting, the CAP Melanoma Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.
Explanatory Notes

A. Procedure
Optimal evaluation of melanocytic lesions requires complete excision that incorporates the full thickness of the involved lesion removed intact.1 "Shave" procedures that do not include the intact base of the lesion should be avoided. Similarly, "punch" procedures may not include intact lateral borders for assessment of symmetry and lateral circumscription, which can be essential for distinction of melanoma from melanocytic nevus.2,3

The use of frozen sections in biopsies or excisions of melanocytic lesions is strongly discouraged.4 Optimal histologic evaluation of cutaneous melanoma requires well-cut, well-stained hematoxylin-and-eosin (H&E) sections prepared from formalin-fixed paraffin-embedded tissue. Frozen sections of sentinel lymph nodes are similarly discouraged, because the manipulation required for intraoperative handling may decrease the sensitivity of the procedure.5

B. Anatomic Site
For cutaneous melanoma, prognosis may be affected by primary anatomic site.6,7

C. Histologic Subtypes
The (modified) World Health Organization (WHO) classification7 of variants of malignant melanocytic neoplasms of the skin includes the following:

- Superficial spreading melanoma
- Nodular melanoma
- Lentigo maligna melanoma
- Acral lentiginous melanoma
- Mucosal-lentiginous melanoma
- Desmoplastic/neurotropic melanoma
- Melanoma arising from blue nevus
- Melanoma arising from a giant congenital nevus
- Melanoma in childhood
- Nevus melanoma
- Persistent melanoma
- Melanoma, not otherwise classified

The WHO list is not exhaustive; this protocol does not preclude use of other diagnostic terms, for example, mucosal lentiginous melanoma, a form commonly observed in the vulva.

There is ongoing research to correlate molecular abnormalities in malignant melanoma, particularly BRAF mutations, with histologic parameters. Given the wide variety of reported mutations in melanoma8 and the lack of predictably effective targeted molecular therapy,9 practical application of such morphologic correlates remains an issue for future protocols.

D. Primary Tumor Thickness (Breslow Thickness) and Anatomic (Clark) Levels7
Maximum tumor thickness is measured with a calibrated ocular micrometer at a right angle to the adjacent normal skin. The upper point of reference is the granular layer of the epidermis of the overlying skin or, if the lesion is ulcerated, the base of the ulcer. The lower reference point is the deepest point of tumor invasion (ie, the leading edge of a single mass or an isolated group of cells deep to the main mass).

If the tumor is transected by the deep margin of the specimen, the depth may be indicated as "at least ___ mm" with a comment explaining the limitation of thickness assessment.

Clark levels are defined as follows:

- I Intraepidermal tumor only
- II Tumor present in but does not fill and expand papillary dermis
- III Tumor fills and expands papillary dermis
IV  Tumor invades into reticular dermis
V  Tumor invades subcutis

Clark levels were previously a primary requirement for subclassifying pT1 lesions according to the American Joint Committee on Cancer (AJCC) 6th edition TNM classification system and are commonly reported. Anatomic level has been replaced by mitotic rate in the AJCC 7th edition tables for subclassifying pT1 lesions as T1a or T1b, but in the text and in a table comment of the AJCC chapter,10 Clark level IV or V is referred to as a tertiary criterion for T1b in cases with no ulceration and "if mitotic rate cannot be determined." Clark level should therefore be reported whenever it would form the basis for upstaging T1 lesions.

The distinction of T1a versus T1b is of significant clinical importance, as the AJCC recommends that sentinel node examination be considered for melanomas stage T1b and above.

E. Ulceration
Ulceration is a dominant prognostic factor in cutaneous melanoma without metastasis,6 and if present, changes the pT stage from T1a to T1b. The presence or absence of ulceration must be confirmed on microscopic examination.11 Melanoma ulceration is defined as the combination of the following features: full-thickness epidermal defect (including absence of stratum corneum and basement membrane); evidence of reactive changes (ie, fibrin deposition, neutrophils); and thinning, effacement, or reactive hyperplasia of the surrounding epidermis in the absence of trauma or a recent surgical procedure. Ulcerated melanomas typically show invasion through the epidermis, whereas nonulcerated melanomas tend to lift the overlying epidermis. Overall, for patients with stage I and II melanomas, the 10-year survival rate is 50% if the tumor is ulcerated and 78% if the tumor is not ulcerated.12 In Cox regression analyses of prognostic factors in cutaneous melanoma that include ulceration, a significantly worse prognosis and a higher risk of metastatic disease have been demonstrated for ulcerated versus non-ulcerated tumors of equivalent thickness.6,11

There is a positive correlation between ulceration and thickness. For ulcerated tumors, the median thickness has been shown to be about 3 mm; for nonulcerated tumors, it is about 1.3 mm. Nevertheless, the adverse prognostic significance of melanoma ulceration has been shown to be independent of tumor thickness. For thin melanomas (1.0 mm or less in thickness), level of invasion is more predictive of survival outcome than ulceration. For melanomas greater than 1.0 mm, ulceration is more predictive than thickness.6 Recent studies suggest that ulceration may lose its independent prognostic significance when mitotic rate is taken into account.13

F. Margins
Microscopically measured distances between tumor and labeled lateral or deep margins are appropriately recorded for melanoma excision specimens because these neoplasms may demonstrate clinical "satellitosis." Nevertheless, a "safe minimum" margin has not been established in the literature. If a lateral margin is involved by tumor, it should be stated whether the tumor is in situ or invasive.

G. Mitotic Rate
A mitotic rate of 1 or more mitotic figure per square millimeter is a powerful adverse prognostic factor for cutaneous melanoma13 and will upstage pT1 lesions from pT1a to pT1b in the 7th edition of the AJCC staging manual. The AJCC recommended method10 is provided below:

“*The recommended approach to enumerating mitoses is to first find the areas in the dermis containing the most mitotic figures, the so called hot spot. After counting the mitoses in the hot spot, the count is extended to adjacent fields until an area corresponding to 1 mm² is assessed. If no hot spot can be found and mitoses are sparse and randomly scattered throughout the lesion, then a representative mitosis is chosen and beginning with that field the count is then extended to adjacent fields until an area corresponding to 1 mm² is assessed. The count then is expressed as the number of mitoses/mm² (ie, an area corresponding to approximately four high power fields at 400x in most microscopes). To obtain accurate measurement, calibration of individual microscopes is recommended. For classifying thin (≤1 mm) melanomas, the threshold for a nonulcerated melanoma to be defined as T1b is ≥1 mitoses/mm².

When the invasive component of tumor is <1 mm² (in area), the number of mitoses present in 1mm² of dermal tissue that includes the tumor should be enumerated and recorded as a number per millimeter
squared. Alternatively, in tumors where the invasive component is <1 mm² in area, the simple presence or absence of a mitosis can be designated as at least 1/mm² (ie, "mitogenic") or 0/mm² (ie, "nonmitogenic"), respectively. At some institutions when mitotic figures are not found after numerous fields are examined, the mitotic count has been described as “<1/mm²”. For most tumor registries the designation “<1/mm²” equals 0 as has been customarily used in the past. This practice may be continued for historical data. For the future, we urge pathologists to list 0 or 1 or more, and this practice should also be demanded by clinicians.

It is a common and appropriate practice with small, thin melanomas to have the technician place multiple sections cut from the block on a single slide. As a guide, we suggest that no more than two slides with such multiple sections be evaluated so that exhaustive evaluation of the lesion is not performed.”

Several points deserve emphasis:

The enumerated mitoses must be melanocytic and dermal.

Implied by the “hot spot” method, as applied in the first paragraph above, is that the identification of even a single mitosis in the dermal component, regardless of the size of that component, is sufficient to report the mitotic rate as greater than or equal to 1 per square millimeter and upstage a thin melanoma to pT1b. This concept has been more explicitly elaborated upon in a recent paper. ¹⁴

The apparent limit on “exhaustive evaluation” is interpreted as indicating that skin specimens containing melanoma should not be processed in a special manner to increase detection of mitoses, but rather should be processed in the same manner as other specimens in that laboratory.

Although the AJCC recommends reporting “0” rather than “none identified” or “less than 1,” for the purposes of cancer registry reporting all of these terms should be considered equivalent and equally acceptable.

H. Microsatellitosis
Microsatellitosis is defined as the presence of tumor nests greater than 0.05 mm in diameter, in the reticular dermis, panniculus, or vessels beneath the principal invasive tumor but separated from it by at least 0.3 mm of normal tissue on the section in which the Breslow measurement was taken. ¹⁵

See also Note O.

I. Vascular Invasion
At least one study¹⁶ has suggested that vascular invasion by melanoma correlates independently with worsened overall survival.

J. Perineural Invasion
Perineural invasion may be seen in melanoma, particularly desmoplastic-neuroid subtypes.⁷ This feature may correlate with an increased risk for local recurrence. It is suggested that the presence of perineural infiltration be noted in surgical pathology reports on melanomas.

K. Tumor-Infiltrating Lymphocytes
A paucity of tumor-infiltrating lymphocytes (TILs) is an adverse prognostic factor for cutaneous melanoma.¹⁷

Tumor-infiltrating lymphocytes may be assessed in a semiquantitative way, as defined below. To qualify as TILs, lymphocytes need to surround and disrupt tumor cells of the vertical growth phase.

TILs Not Identified: No lymphocytes present, or lymphocytes present but do not infiltrate tumor at all.

TILs Nonbrisk: Lymphocytes infiltrate melanoma only focally or not along the entire base of the vertical growth phase.

TILs Brisk: Lymphocytes diffusely infiltrate the entire base of the vertical growth phase (Figure 1, A) or the entire invasive component of the melanoma (Figure 1, B).
L. Tumor Regression
Characteristic features of regression include replacement of tumor cells by lymphocytic inflammation (definitional), as well as attenuation of the epidermis and nonlaminated dermal fibrosis with inflammatory cells, melanophagocytosis, and telangiectasia.

Complete regression carries adverse prognostic importance in invasive melanomas, as does regression involving more than 75% of the lesion.\(^{17}\)

M. Growth Patterns and Phases
The prognostic significance of histologic type is less significant than the growth patterns and depth of infiltration displayed by those histologic types. For example, superficial spreading melanomas, by definition, demonstrate prominent radial growth and have a better prognosis than nodular melanomas, which predominantly demonstrate vertical growth.\(^{18}\)

**Radial Growth Phase:** Tumor demonstrates a uniform cytological appearance and is generally wider than it is deep. One commonly applied criterion is presence of melanoma in situ 3 or more rete ridges beyond the invasive component.

**Vertical Growth Phase:** Vertical growth phase is an adverse prognostic factor for cutaneous melanoma. Nodular melanomas are by definition vertical growth phase tumors. Vertical growth pattern in superficial spreading melanoma is defined as the presence of 1 or more dermal clusters larger than the largest epidermal cluster and/or the presence of any mitotic activity in the dermis.\(^{19}\)

N. Lymph Nodes
Removal of sentinel lymph nodes may be performed for patients with primary localized cutaneous melanomas with a thickness of 1 mm or greater, and recent data indicates that it also may be justified for lesions less than 1 mm thick (incidence of sentinel lymph node metastasis is about 4% to 6% in so-called thin melanomas versus about 15% for melanomas ≥1 mm thick).\(^{20}\) Frozen section analysis of sentinel lymph nodes is not advised.\(^{5}\) Review of the H&E-stained slides from multiple levels through serially sectioned sentinel lymph nodes increases the sensitivity of detecting microscopic melanoma metastasis; routine analysis (H&E-stained sections of the cut surfaces of a simply bisected lymph node) may lead to a false-negative rate of 10% to 15%. The use of immunohistochemical stains (eg, for HMB-45 or MART-1) further increases the sensitivity of detection of microscopic melanoma metastases and should also be considered in the examination of sentinel lymph nodes. Although immunohistochemical staining should be used in conjunction with and not in place of standard histologic
examination, immunohistochemically identified micrometastases are accepted as representing greater than N0 disease by the 7th edition of the AJCC staging system.\textsuperscript{10}

For histologic examination, whether for sentinel node analysis or for routine regional lymph node evaluation, the entire node, except tissue collected for consented research protocols, should be submitted. For routine evaluation, large lymph nodes may be bisected or sliced at 2-mm intervals, whereas smaller nodes (<5 mm) may be submitted whole.

A number of studies\textsuperscript{21-23} have suggested the sentinel lymph node tumor burden or the pattern of metastasis in the sentinel node (such as the S Classification)\textsuperscript{24} may be useful in predicting patients who have additional disease in nonsentinel nodes and thus would help select patients who might benefit from complete lymph node dissection. Investigators have suggested that the amount or pattern of the disease in the sentinel node may also serve as a prognostic factor. If such results are validated and found to be reproducible, then they may be an issue for future protocols.

Although not required for AJCC staging, current National Comprehensive Cancer Network (NCCN) guidelines\textsuperscript{25} recommend recording the size and location of tumor present in a positive sentinel node. These are included as optional elements in this protocol.

O. TNM and Stage Groupings
The TNM Staging System of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended by this protocol.\textsuperscript{10,26}

Changes in the 7th edition AJCC Cancer Staging Manual of importance to practicing pathologists include:
- Assignment of pT1b status to lesions less than 1mm thick with 1 or more mitoses per mm\textsuperscript{2}
- Relegation of Clark level IV or V to tertiary importance in assignment of pT1b status
- Classification of the presence of any nodal melanoma cells (including isolated tumor cells [ITCs]) as nodal involvement (>pN0)
- Allowing purely immunohistochemical detection of nodal metastasis

Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy.\textsuperscript{10}

In virtually all studies of cutaneous melanoma, tumor thickness has been shown to be a dominant prognostic factor,\textsuperscript{7,10,16} and it forms the basis for the stratification of pT. Clark levels are also commonly used to indicate depth of invasion of the primary tumor,\textsuperscript{7,10,17,26} but are less predictive of clinical outcome than mitotic activity.\textsuperscript{20}

By AJCC/UICC convention, the designation "T" refers to a primary tumor that has not been previously treated. The symbol "p" refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination of surgically removed tissues. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies pathologic examination of distant lesions.

T Category Considerations
Pathologic (microscopic) assessment of the primary tumor is required for proper staging. Therefore, excision of the primary tumor, rather than incisional biopsy, is advised. The T classification of melanoma is based on the thickness of the primary tumor, presence or absence of ulceration, mitotic rate, and in some cases its anatomic level of invasion (see also Notes D, E, and G).

N Category Considerations (see also Note N)
The regional lymph nodes are the most common sites of metastasis. The widespread use of cutaneous lymphoscintigraphy, lymphatic mapping, and sentinel lymph node biopsies has greatly enhanced the ability to identify the presence of lymph node metastasis.\textsuperscript{10} By convention, the term regional lymph nodal metastasis refers to disease confined to 1 draining nodal basin or 2 contiguous draining nodal basins, as in patients with nodal disease in combinations of femoral/iliac, axillary supraclavicular, cervical supraclavicular, axillary/femoral, or bilateral axillary or femoral metastases. Metastasis to nondraining nodal basin(s) is considered M1 disease.
Isolated Tumor Cells, Micrometastasis, and Sentinel Lymph Nodes\textsuperscript{27,28}

The previous edition of this protocol employed the use of ITC terminology analogous to that published for breast cancer. The 7th edition staging system defines nodal involvement by the presence of any tumor cells regardless of quantity, size, or mode of detection (ie, >pN0).

Sentinel lymph node identification and evaluation may be included in the surgical approach to cutaneous melanoma. A sentinel lymph node is defined as the first node to receive lymphatic drainage from a primary tumor. There may be more than 1 sentinel node for some tumors. The clinical rationale for sentinel lymph node identification and separate evaluation is based on the assumption that metastatic involvement of a sentinel node increases the likelihood that other, more distant nodes may also contain metastatic disease. Conversely, if sentinel nodes are negative, other regional nodes would be less likely to contain metastasis.

In almost all studies using Cox regression analysis, either the number of regional lymph nodes containing metastases or the percentage of regional nodes containing metastases more strongly predicted outcome than the size of metastasis.\textsuperscript{6,11,29} Patients with 1 involved lymph node have longer survivals compared to patients with any combination of 2 or more involved nodes, regardless of the size of the metastasis. In their review of reported studies, the AJCC Melanoma Staging Committee found no compelling evidence that the gross dimension of lymph nodes metastases was an independent predictor of outcome.\textsuperscript{30}

Micrometastasis versus Macrometastasis\textsuperscript{10}

The AJCC 7th edition staging system defines micrometastasis as nodal metastasis diagnosed after pathologic examination of sentinel lymph node biopsy or completion lymphadenectomy (if performed), in patients without clinical or radiologic evidence of metastasis, ie, “clinically occult.” Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension. Because complete clinical staging information may not always be available to the pathologist, it may be advisable in cases with bulky nodal disease to add a comment to the report to the effect that if nodal disease was clinically apparent, that upstaging to pN1b or pN2b would be appropriate and that clinical correlation is needed. Centers receiving nodal dissections routinely may wish to make submission of presence or absence of clinical adenopathy part of their standard requisition data.

In-transit metastasis/satellitosis is used in the 7th edition AJCC staging system for definition of N2c disease. Satellitosis by definition occurs within 2 cm of the primary tumor. In-transit metastasis is defined as intralymphatic tumor in skin or subcutaneous tissue more than 2 cm from the primary tumor but not beyond the nearest regional lymph node basin. The presence of in-transit metastasis between the primary tumor and the regional lymph nodes portends a poor prognosis.

The presence of clinical or microscopic satellite lesions around a primary melanoma and in-transit metastases both portend a poor prognosis, and an analysis of the available data by the AJCC Melanoma Staging Committee revealed no significant difference in survival between the two, both of which are associated with a prognosis equivalent to multiple lymph node metastases.\textsuperscript{10}

M Category Considerations

The category “MX” has been eliminated from the AJCC/UICC TMN system.\textsuperscript{10} Unless there is clinical or pathologic evidence of distant metastasis the stage is classified as clinical M0 (ie, no distant metastasis). pM should only be reported when metastases have been documented by pathologic examination, that is, pM1 disease. pMX and pM0 should not be reported by the pathologist.

Pathologic Stage Groupings

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
</tbody>
</table>

13
Stage IIIB  
T3b N0 M0
T4a N0 M0
Stage IIIC  
T4b N0 M0
Stage IIIA  
T1-4a N1a M0
T1-4a N2a M0
Stage IIIB  
T1-4b N1a M0
T1-4b N2a M0
T1-4a N1b M0
T1-4a N2b M0
T1-4a N2c M0
Stage IIIC  
T1-4b N1b M0
T1-4b N2b M0
T1-4b N2c M0
Any T N3 M0
Stage IV   
Any T Any N M1

Note that for cutaneous melanoma, clinical and pathologic stage groupings differ for stage III. The complete clinical stage groupings are shown below for comparison.

**Clinical Stage Groupings**

Stage 0  
Tis N0 M0
Stage IA  
T1a N0 M0
Stage IB  
T1b N0 M0
T2a N0 M0
Stage IIA  
T2b N0 M0
T3a N0 M0
Stage IIB  
T3b N0 M0
T4a N0 M0
Stage IIC  
T4b N0 M0
Stage III  
Any T ≥N1 M0
Stage IV   
Any T Any N M1

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

Post-therapy stage (yTNM) documents the extent of the disease for patients whose first course of therapy includes systemic or radiation treatment prior to surgical resection or when systemic therapy or radiation is primary treatment with no surgical resection. The extent of disease is classified using the same T, N, and M definitions and identified as post-treatment with a “yc” or “ yp” prefix (ycT, ycN, ycTNM; ypT, ypN, ypTNM).

Retreatment classification (rTNM) is used because information gleaned from therapeutic procedures and from extent of disease defined clinically may be prognostic for patients with recurrent cancer after a disease-free interval. It is important to understand that the rTNM classification does not change the original clinical or pathologic staging of the case.

Autopsy classification (aTNM) is used to stage cases of cancer not recognized during life and only recognized postmortem.

**Additional Descriptors**

**Residual Tumor (R)**

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, as follows.
RX  Presence of residual tumor cannot be assessed
R0  No residual tumor
R1  Microscopic residual tumor
R2  Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**Lymph-Vascular Invasion**
Lymph-vascular invasion (LVI) indicates whether microscopic lymph-vascular invasion is identified and includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

**P. Pretreatment Serum Lactate Dehydrogenase and Serum Albumin**
Data from numerous studies have suggested that an elevated serum level of LDH is a stage-independent prognostic factor for decreased survival in melanoma. In these studies, pretreatment LDH elevation has been variably defined as serum levels greater than 200 to 225 U/L or as levels elevated above the reference range of the reference laboratory.\(^6,12,31\) It is recommended that any elevation above reference range should be checked by repeat LDH testing after at least 24 hours. For stage IV melanoma, a decreased serum albumin level (≤3.5 to 4.0 g/dL) has also been shown to be an independent adverse prognostic factor.\(^6,12,31\)

**References**